Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

NCT04679064 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

427

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Niraparib
DRUG: Dostarlimab
DRUG: Pegylated liposomal doxorubicin
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Topotecan
DRUG: Bevacizumab

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborators

[object Object]